1,179 research outputs found
Quantitative Concentrations of Sodium and Potassium Released from Brown Coal and Pine Wood in a Laminar Premixed Flame Using Libs
A quantitative point measurement of total sodium and potassium released during combustion of Australian Loy Yang brown coal particles (23 ± 3 mg) and pine wood pellets (63 ± 3 mg) has been performed using laser-induced breakdown spectroscopy (LIBS) in a laminar premixed methane flame at the equivalence ratio (Φ) of 1.287. Calibration was performed using droplets of sodium sulfite (Na2SO3) and potassium sulphate (K2SO4) entrained into the flame. A correction to the calibration curve was applied to compensate for the significant absorption effect caused by atomic alkalis in outer seeded flame, which significantly improved the calibration reliability especially at high concentrations. Hence quantitative release of sodium and potassium during the three phases of combustion, namely devolatilization, char and ash cooking, were obtained. The concentration of total sodium in the plume released from combustion of pine wood pellets during the devolatilization reached up to 15 ppm indicating significant sodium was released in various forms. The strongest concentrations of total sodium and potassium released during char phase of both coal and wood reaching up to 21.3 and 2.4 ppm, 15.5 and 26.3 ppm, respectively. Limit of Detection (LOD) of sodium and potassium with LIBS in the present setup were estimated to be 0.029 and 0.072 ppm, respectively.Li-Jen Hsu, Zeyad Alwahabi, Graham Nathan, Peter Ashman, Keith Kinghttp://www.chemeca2010.com/abstract/226.as
Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials.
BackgroundSentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [(99m)Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrandomized, within-patient, phase 3 trials designed to assess the lymphatic mapping performance.MethodsA total of 13 centers contributed 148 patients with breast cancer. Each patient received [(99m)Tc]tilmanocept and vital blue dye (VBD). Lymph nodes identified intraoperatively as radioactive and/or blue stained were excised and histologically examined. The primary endpoint, concordance (lower boundary set point at 90 %), was the proportion of nodes detected by VBD and [(99m)Tc]tilmanocept.ResultsA total of 13 centers contributed 148 patients who were injected with both agents. Intraoperatively, 207 of 209 nodes detected by VBD were also detected by [(99m)Tc]tilmanocept for a concordance rate of 99.04 % (p < 0.0001). [(99m)Tc]tilmanocept detected a total of 320 nodes, of which 207 (64.7 %) were detected by VBD. [(99m)Tc]Tilmanocept detected at least 1 SLN in more patients (146) than did VBD (131, p < 0.0001). In 129 of 131 patients with ≥1 blue node, all blue nodes were radioactive. Of 33 pathology-positive nodes (18.2 % patient pathology rate), [(99m)Tc]tilmanocept detected 31 of 33, whereas VBD detected only 25 of 33 (p = 0.0312). No pathology-positive SLNs were detected exclusively by VBD. No serious adverse events were attributed to [(99m)Tc]tilmanocept.Conclusion[(99m)Tc]Tilmanocept demonstrated success in detecting a SLN while meeting the primary endpoint. Interestingly, [(99m)Tc]tilmanocept was additionally noted to identify more SLNs in more patients. This localization represented a higher number of metastatic breast cancer lymph nodes than that of VBD
Kinematic Structure of H2 and [Fe II] in the Bipolar Planetary Nebula M 2-9
We present high-dispersion long-slit IR spectra of the double-shell bipolar
planetary nebula M 2-9 in the emission lines [Fe II] 16435 and H2 v=1--0 S(1)
21218. H2 spectra reveal for the first time the kinematic structure of the
outer shell in M 2-9. Kinematics of the inner shell, traced by [Fe II],
resemble those of optical lines like [N II]. [Fe II] and H2 shells have
expansion speeds roughly proportional to distance from the star (``Hubble''
flows) and share the same dynamical age of 1200--2000 yr, depending on the
distance to M 2-9. Thus, the inner ionized lobes and outer molecular lobes, as
well as the molecular torus and ``outer loops'' measured by other observers,
were all formed around the same time. Consequently, their nested structure
likely arises from an excitation gradient rather than independent ejections. H2
and [Fe II] emission is distributed more uniformly than [N II], and IR lines
are not dominated by the moving ionization pattern like visual-wavelength
lines. We suggest that this is because IR lines of [Fe II] and H2 are excited
by relatively isotropic far-UV radiation (Balmer continuum), whereas optical
lines respond to a directed rotating beam of Lyman continuum. Finally, we
highlight intriguing similarities between M 2-9 and the Homunculus of eta
Carinae, despite the different central engines powering the two nebulae.Comment: comments: 16 pages, 5 Figs, Fig 1 in color, accepted by AJ (August
2005
A Spectroscopic Study of Mass Outflows in the Interacting Binary RY Scuti
The massive interacting binary RY Scuti is an important representative of an
active mass-transferring system that is changing before our eyes and which may
be an example of the formation of a Wolf-Rayet star through tidal stripping.
Utilizing new and previously published spectra, we present examples of how a
number of illustrative absorption and emission features vary during the binary
orbit. We identify spectral features associated with each component, calculate
a new, double-lined spectroscopic binary orbit, and find masses of 7.1 +/- 1.2
M_sun for the bright supergiant and 30.0 +/- 2.1 M_sun for the hidden massive
companion. Through tomographic reconstruction of the component spectra from the
composite spectra, we confirm the O9.7 Ibpe spectral class of the bright
supergiant and discover a B0.5 I spectrum associated with the hidden massive
companion; however, we suggest that the latter is actually the spectrum of the
photosphere of the accretion torus immediately surrounding the massive
companion. We describe the complex nature of the mass loss flows from the
system in the context of recent hydrodynamical models for beta Lyr, leading us
to conclude RY Scuti has matter leaving the system in two ways: 1) a bipolar
outflow from winds generated by the hidden massive companion, and 2) mass from
the bright O9.7 Ibpe supergiant flowing from the region near the L2 point to
fill out a large, dense circumbinary disk. This circumbinary disk (radius ~ 1
AU) may feed the surrounding double-toroidal nebula (radius ~ 2000 AU).Comment: 41 pages with 7 tables and 11 figures, accepted to Ap
Collective decision making by rational individuals
The patterns and mechanisms of collective decision making in humans and animals have attracted both empirical and theoretical attention. Of particular interest has been the variety of social feedback rules and the extent to which these behavioral rules can be explained and predicted from theories of rational estimation and decision making. However, models that aim to model the full range of social information use have incorporated ad hoc departures from rational decision-making theory to explain the apparent stochasticity and variability of behavior. In this paper I develop a model of social information use and collective decision making by fully rational agents that reveals how a wide range of apparently stochastic social decision rules emerge from fundamental information asymmetries both between individuals and between the decision makers and the observer of those decisions. As well as showing that rational decision making is consistent with empirical observations of collective behavior, this model makes several testable predictions about how individuals make decisions in groups and offers a valuable perspective on how we view sources of variability in animal, and human, behavior
Integration of hormonal signaling networks and mobile microRNAs is required for vascular patterning in Arabidopsis roots
Peer reviewe
A Catalog of Chandra X-ray Sources in the Carina Nebula
We present a catalog of ~14,000 X-ray sources observed by the ACIS instrument
on the Chandra X-ray Observatory within a 1.42 square degree survey of the
Great Nebula in Carina, known as the Chandra Carina Complex Project (CCCP).
This study appears in a Special Issue of the ApJS devoted to the CCCP. Here, we
describe the data reduction and analysis procedures performed on the X-ray
observations, including calibration and cleaning of the X-ray event data, point
source detection, and source extraction. The catalog appears to be complete
across most of the field to an absorption-corrected total-band luminosity of
~10^{30.7} erg/s for a typical low-mass pre-main sequence star. Counterparts to
the X-ray sources are identified in a variety of visual, near-infrared, and
mid-infrared surveys. The X-ray and infrared source properties presented here
form the basis of many CCCP studies of the young stellar populations in Carina.Comment: Accepted for the ApJS Special Issue on the Chandra Carina Complex
Project (CCCP), scheduled for publication in May 2011. All 16 CCCP Special
Issue papers are available at
http://cochise.astro.psu.edu/Carina_public/special_issue.html through 2011 at
least. 29 pages, 11 figure
Electronic Sun Journal Versus Self-report Sun Diary: A Comparison of Recording Personal Sunlight Exposure Methods
This research compared personal sunlight exposure times monitored electronically within suburban Australian environments against self-report paper journals for determining the timing and total duration of individual exposure to daily solar radiation. A total of 90 Electronic Sun Journal (ESJ) daily readings and self-report timing and duration estimates of exposure for weekend and weekdays were compared. A Wilcoxon ranked sign test showed a significant difference (V = 157, p < 0.001) between the duration of exposure recorded electronically and the duration of exposure that was self-reported in a diary. There was also found to be a statistically significant difference between total exposure time measured using both methods for weekends (V = 10, p < 0.001) and weekdays (V = 87, p < 0.001). General trends in outdoor exposure timing confirmed that the most frequent daily exposures received over the weekend occurred between one and two hours earlier than the most frequent exposures received on weekdays. This preliminary research found that exposure durations as recorded by the ESJ were longer on the weekends compared to weekdays (W = 402, p < 0.001) and confirmed that the ESJ is a viable alternative to self-reporting diaries
Crisp1 and alopecia areata in C3H/HeJ mice
Alopecia areata (AA), a cell mediated autoimmune disease, is the second most common form of hair loss in humans. While the autoimmune disease is responsible for the underlying pathogenesis, the alopecia phenotype is ultimately due to hair shaft fragility and breakage associated with structural deficits. Quantitative trait genetic analyses using the C3H/HeJ mouse AA model identified cysteine-rich secretory protein 1 (Crisp1), a hair shaft structural protein, as a candidate gene within the major AA locus. Crisp1 transcripts in the skin at various times during disease development were barely detectable. In situ hybridization identified Crisp1 expression within the medulla of hair shafts from clinically normal strains of mice but not C3H/HeJ mice with AA. Follow-up work with 5-day-old C3H/HeJ mice with normal hair also had essentially no expression of Crisp1. Other non-inflammatory based follicular dystrophy mouse models with similar hair shaft abnormalities also have little or no Crisp1 expression. Shotgun proteomics, used to determine strain difference in hair proteins, confirmed that there was very little CRISP1 within normal C3H/HeJ mouse hair in comparison to 11 other strains. However, mutant mice with hair medulla defects also had undetectable levels of CRISP1 in their hair. Crisp1 null mice had normal skin, hair follicles, and hair shafts indicating that the lack of the CRISP1 protein does not translate directly into defects in the hair shaft or hair follicle. These results suggest that CRISP1 may be an important structural component of mouse hair and that its strain-specific dysregulation may indicate a predisposition to hair shaft disease such as AA.Fil: Sundberg, John P.. Vanderbilt University; Estados Unidos. The Jackson Laboratory; Estados UnidosFil: Awgulewitsch, Alejandro. Medical University of South Carolina; Estados UnidosFil: Pruett, Nathan D.. Medical University Of South Carolina; Estados UnidosFil: Potter, Cristhoper S.. The Jackson Laboratory; Estados UnidosFil: Silva, Kathleen A.. The Jackson Laboratory; Estados UnidosFil: Stearns, Timothy M.. The Jackson Laboratory; Estados UnidosFil: Sundberg, Beth A.. The Jackson Laboratory; Estados UnidosFil: Weigel Muñoz, Mariana. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Instituto de BiologĂa y Medicina Experimental. FundaciĂłn de Instituto de BiologĂa y Medicina Experimental. Instituto de BiologĂa y Medicina Experimental; ArgentinaFil: Cuasnicu, Patricia Sara. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Instituto de BiologĂa y Medicina Experimental. FundaciĂłn de Instituto de BiologĂa y Medicina Experimental. Instituto de BiologĂa y Medicina Experimental; ArgentinaFil: King, Lloyd E. Jr. Vanderbilt University; Estados UnidosFil: Rice, Robert H.. University of California. Department of Nutrition and Department of Environmental Toxicology; Estados Unido
Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial
Compelling data have linked disease progression in patients with idiopathic pulmonary fibrosis (IPF) with lung dysbiosis and the resulting dysregulated local and systemic immune response. Moreover, prior therapeutic trials have suggested improved outcomes in these patients treated with either sulfamethoxazole/ trimethoprim or doxycycline. These trials have been limited by methodological concerns. This trial addresses the primary hypothesis that long-term treatment with antimicrobial therapy increases the time-to-event endpoint of respiratory hospitalization or all-cause mortality compared to usual care treatment in patients with IPF. We invoke numerous innovative features to achieve this goal, including: 1) utilizing a pragmatic randomized trial design; 2) collecting targeted biological samples to allow future exploration of 'personalized' therapy; and 3) developing a strong partnership between the NHLBI, a broad range of investigators, industry, and philanthropic organizations. The trial will randomize approximately 500 individuals in a 1:1 ratio to either antimicrobial therapy or usual care. The site principal investigator will declare their preferred initial antimicrobial treatment strategy (trimethoprim 160 mg/ sulfamethoxazole 800 mg twice a day plus folic acid 5 mg daily or doxycycline 100 mg once daily if body weight is < 50 kg or 100 mg twice daily if ≥50 kg) for the participant prior to randomization. Participants randomized to antimicrobial therapy will receive a voucher to help cover the additional prescription drug costs. Additionally, those participants will have 4-5 scheduled blood draws over the initial 24 months of therapy for safety monitoring. Blood sampling for DNA sequencing and genome wide transcriptomics will be collected before therapy. Blood sampling for transcriptomics and oral and fecal swabs for determination of the microbiome communities will be collected before and after study completion. As a pragmatic study, participants in both treatment arms will have limited in-person visits with the enrolling clinical center. Visits are limited to assessments of lung function and other clinical parameters at time points prior to randomization and at months 12, 24, and 36. All participants will be followed until the study completion for the assessment of clinical endpoints related to hospitalization and mortality events. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02759120
- …